Die Wissenschaft ist das beste Werkzeug, das wir haben, um zu unterscheiden, was wahr ist und was wir uns wünschen würden wahr zu sein. Ein großer Teil davon wird von Parteien finanziert, die ein Interesse am Ergebnis haben. Diese Kombination ist gut dokumentiert. Interne Memos und Gerichtsakten zeigen vier Vorgehensweisen.
Eine Zucker-Industriegruppe zahlte für eine Überprüfung aus dem Jahr 1967, die Fett als Ursache benannte. Die Tabakindustrie finanzierte Zweifel. Pharmahersteller ließen günstige Studien von Ghostwritern verfassen, und negative Studien blieben unveröffentlicht. Genau diese Fälle weisen auf eine Methode für jede Studie hin: die Finanzierung herausfinden, die Vorregistrierung prüfen, harte Endpunkte bevorzugen und Replikationen gewichten.
What This Is
Industry influence on science is a documented record of four repeated moves: paying for a convenient review, funding doubt, ghostwriting favorable papers, and burying negative trials. Each move has left a paper trail since the 1960s.
The Documented Cases
These cases span more than 40 years, from a 1967 journal review to a 2007 guilty plea.
Sugar, fat, and a paid-for review
In 1967 the New England Journal of Medicine ran a review that discounted sugar's link to heart disease and pointed instead at fat and cholesterol. A sugar-industry trade group, the Sugar Research Foundation, had paid Harvard nutrition researchers to write it. The group set the review's objective, supplied material for it, and commented on the drafts. None of that was disclosed, because disclosure was not required at the time. That framing helped shape the low-fat dietary advice that followed for decades (Kearns 2016). Those same decades saw obesity and type-2 diabetes climb, both now driven largely by industry-built ultra-processed food heavy in sugar, fat, and salt.
The tobacco playbook
In 1969 a tobacco executive put the strategy in writing:
Doubt is our product, since it is the best means of competing with the body of fact that exists in the mind of the general public.
Facing mounting evidence that smoking caused disease, the industry mostly left individual findings alone. It funded research bodies and public relations to keep the overall picture looking unsettled, turning a largely closed question into a public controversy. Manufacturing doubt costs less than manufacturing evidence. It works because real science always has some genuine uncertainty, so manufactured doubt is hard to tell apart from it. Other industries facing inconvenient findings took up the same approach (Brandt 2012).
What the funding data show
One review pooled 75 studies that compared industry-funded research with independent research on the same products. The sponsored work reported favorable results about 27% more often and favorable conclusions about 34% more often. Standard quality checks did not explain the gap (Lundh 2017). Across the literature, who funded a study predicts which way it comes out, even after you account for how well it was designed.
Ghostwriting
In litigation files for a hormone-therapy product, ghostwritten reviews promoted its benefits and played down the breast-cancer risk that a large independent trial later confirmed (Fugh-Berman 2010). The pattern repeated for the painkiller rofecoxib, sold as Vioxx: company-drafted manuscripts had outside academics added as first authors after the writing was largely finished (Ross 2008).
The missing trials, and the fix
Of 74 antidepressant trials a regulator reviewed, nearly every one it judged positive reached print. Most of the unfavorable ones did not, or were written up to read positive. The journal record showed 94% of trials succeeding; the regulator had counted 51% (Turner 2008). Preregistration closes this gap: a trial posts its main outcome to a public registry before it starts, so no one can move the target after the numbers land.
OxyContin shows the marketing side of the same problem. Its maker sold it from 1996 with a claim that the formulation carried a low risk of addiction. Prescribing and misuse climbed together. In 2007 the company and three executives pleaded guilty to understating that risk.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Evidence And Methods
Sponsored trials reported favorable results about 27% more often, across 75 studies
Across dozens of comparisons, industry-funded trials came out favorable about 27% more often than independent ones, and the usual quality checks did not account for the gap.
Lundh and colleagues, in a Cochrane methodology review, examined studies that compared industry-sponsored with non-industry-sponsored drug and device research. Industry sponsorship was associated with more favorable efficacy results (risk ratio 1.27, 95% confidence interval 1.17 to 1.37) and more favorable conclusions (risk ratio 1.34, 95% confidence interval 1.19 to 1.51). Sponsored studies also showed less agreement between their results and their stated conclusions. The association held after accounting for methodological quality such as randomization and blinding, which means the standard risk-of-bias tools do not capture it.
Treat funding source as a piece of evidence in itself. Weight an independent replication above a single sponsor-funded trial, whatever the trial's size.
The study · 1
Lundh et al., industry sponsorship and research outcome (Cochrane methodology review) · Cochrane Database Syst Rev 2017;2:MR000033
Journals showed 94% of antidepressant trials positive; the regulator's files showed 51%
Regulators held the results of 74 antidepressant trials. Almost every trial with a good result got published, while most trials with a poor result never did, or were written up to look better than they were. Someone reading only the journals would think nearly every trial succeeded; the full record showed about half did.
Turner and colleagues compared 74 antidepressant trials registered with the US Food and Drug Administration between 1987 and 2004 against what reached the published literature. Of 38 studies the FDA judged positive, 37 were published. Of 36 studies with negative or questionable results, 22 were not published at all and 11 were published in a form that conveyed a positive outcome. The published record therefore showed 94% of trials as positive against the FDA's 51%, and pooling published and unpublished data together reduced the pooled effect size by about 32%, with individual drugs inflated between 11% and 69%.
One published positive trial can mislead on its own, because the trials that failed may simply be missing. Prefer a systematic review that searched trial registries, not journals alone, and check whether the outcome was preregistered.
The study · 1
Turner et al., selective publication of antidepressant trials and its influence on apparent efficacy · N Engl J Med 2008;358(3):252-260
In 1967 the sugar industry secretly paid Harvard researchers to blame fat, not sugar
In the 1960s a sugar-industry group quietly paid Harvard researchers to write an influential review that pointed the finger at dietary fat, not sugar, for heart disease. The payment and the industry's hand in shaping it were not disclosed at the time.
Kearns, Schmidt and Glantz analyzed surviving correspondence between the Sugar Research Foundation (SRF) and Harvard nutrition researchers. The SRF paid the equivalent of roughly 50,000 US dollars in 2016 terms for a two-part literature review, published in the New England Journal of Medicine in 1967, that discounted the evidence linking sucrose to coronary heart disease and directed attention to fat and cholesterol. The documents show the SRF set the review's objective, supplied articles for it, and received and commented on drafts. The funding and the industry role were not disclosed, and disclosure was not required by the journal at the time.
When a review reaches a tidy conclusion, look for who paid for it and whether the funder helped frame the question. Here the undisclosed sponsorship is exactly what let the conclusion stand unquestioned for decades.
The study · 1
Kearns, Schmidt and Glantz, sugar industry and coronary heart disease research: a historical analysis of internal industry documents · JAMA Intern Med 2016;176(11):1680-1685
Industry funding tracked with pro-industry conclusions at 3.6 times the odds, across 1,140 studies
Reviewing more than a thousand studies, researchers found industry money was common in medical research and was linked to conclusions that favored the funder, and sometimes to results being held back or delayed.
Bekelman, Li and Gross systematically reviewed the evidence on financial conflicts of interest in biomedical research, drawing on 1,140 original articles. About a quarter of investigators had industry affiliations and about two thirds of academic institutions held equity in startups that sponsored research within those institutions. Pooling eight studies that examined the link between industry sponsorship and outcomes gave an aggregate odds ratio of 3.60 (95% confidence interval 2.63 to 4.91) for industry-favorable conclusions. The review also documented industry practices of restricting publication and withholding data.
Read the disclosure statement and the data-availability statement together. A funder able to delay or withhold results shapes the published record before any analysis is even reported.
The study · 1
Bekelman, Li and Gross, scope and impact of financial conflicts of interest in biomedical research: a systematic review · JAMA 2003;289(4):454-465
A 1969 tobacco memo called doubt its product to keep the science looking unsettled
Faced with mounting evidence that smoking caused disease, the tobacco industry did not deny it outright. It paid to keep the science looking unsettled, summed up in an internal line: doubt is our product. The same approach was later reused on other health questions.
Brandt's history, built on tobacco-industry documents released through litigation, describes a strategy that began with a 1953 public-relations plan and ran through industry-funded research bodies such as the Council for Tobacco Research. A 1969 Brown and Williamson memo stated that doubt is our product, since it is the best means of competing with the body of fact that exists in the mind of the general public. The strategy did not dispute individual findings; it framed a settled question as an open scientific controversy, funding work and commentary that emphasized uncertainty. Brandt argues this template of manufactured doubt was later borrowed by other industries facing inconvenient science.
Manufactured doubt can look like ordinary scientific debate. When an industry funds the voices calling a well-settled question open, treat that funding as part of the evidence you are weighing.
The study · 1
Brandt, inventing conflicts of interest: a history of tobacco industry tactics · Am J Public Health 2012;102(1):63-71
A hormone-therapy maker ghostwrote journal reviews that played down breast-cancer risk
A drug company hired writers to produce medical-journal articles favorable to its hormone therapy, then had respected academics put their names on them. Readers saw independent experts; the words came from the company's writers.
Fugh-Berman analyzed documents released in litigation over hormone therapy. The manufacturer engaged a medical-communications company to draft review articles and commentaries that emphasized the benefits of hormone therapy and countered emerging concerns, including the link to breast cancer, and then recruited academically affiliated authors to appear as the named authors. The scheme came to light in documents disclosed after the Women's Health Initiative trial reported that combined hormone therapy carried serious harms, contradicting much of the promotional literature.
A named academic author is not a guarantee of independent authorship. Read the acknowledgements and funding lines for editorial assistance or a medical-communications firm, which is where ghostwriting is disclosed when it is disclosed at all.
The study · 1
Fugh-Berman, the haunting of medical journals: how ghostwriting sold hormone therapy · PLoS Med 2010;7(9):e1000335
The maker of Vioxx drafted trial papers, then recruited academics to be the named authors
In lawsuits over the painkiller rofecoxib, marketed as Vioxx, documents showed the company had drafted journal articles internally and then found university researchers to appear as the lead authors.
Ross and colleagues reviewed documents produced in litigation over rofecoxib. For several clinical-trial reports, a manuscript was drafted by a company employee or a company-paid writer before an externally affiliated academic author was recruited to appear as the first author. The documents also showed guest authorship in review articles used to support the drug. The paper quantified the pattern across a defined set of publications, distinguishing those who actually wrote a paper from bylines added after the writing was largely complete.
Named authorship and actual authorship can differ. When several papers on one product share a house style and a single sponsor, ask who wrote the first draft.
The study · 1
Ross et al., guest authorship and ghostwriting in publications related to rofecoxib · JAMA 2008;299(15):1800-1812
In 2007 OxyContin's maker pleaded guilty to understating the drug's addiction risk
The maker of OxyContin ran an aggressive campaign that told doctors the drug rarely caused addiction. Prescriptions and misuse rose together, and in 2007 the company admitted in court that it had misled about the addiction risk.
Van Zee describes the marketing of OxyContin from its 1996 launch: a bonus-driven sales force, expansion of use well beyond cancer pain, branded promotional items, sponsored education, and a central claim that the controlled-release formulation carried a low risk of addiction. Sales rose from about 48 million US dollars in 1996 to roughly 1.1 billion by 2000. In 2007 the manufacturer and three executives pleaded guilty to federal charges of misbranding the drug with respect to its risk of abuse and agreed to penalties of around 600 million US dollars.
A manufacturer's claims about a product's safety are not the same as evidence of it. Weigh independent surveillance data over a company's reassurance, particularly when a product is being promoted for wider use.
The study · 1
Van Zee, the promotion and marketing of OxyContin: commercial triumph, public health tragedy · Am J Public Health 2009;99(2):221-227
After preregistration became standard in 2000, heart-trial success fell from 57% to 8%
Before researchers had to declare their main question in advance, most big heart trials reported success. After advance registration became the norm, almost none did, which suggests the earlier success rate owed a great deal to outcomes chosen after the results were already in.
Kaplan and Irvin examined 55 large trials funded by the US National Heart, Lung, and Blood Institute between 1970 and 2012 testing drugs or dietary supplements against hard outcomes. The share reporting a significant benefit on the prespecified primary outcome fell from 17 of 30 (57%) in trials before 2000 to 2 of 25 (8%) in trials from 2000 onward. The authors link the drop to the requirement, taking hold around 2000, to register the primary outcome and analysis plan on ClinicalTrials.gov before the trial began, which constrains the later selection of a favorable endpoint.
Preregistration is one of the strongest signals that a result can be trusted. Check whether the primary outcome was posted before enrolment began, and be wary of a headline finding that was not the outcome first named.
The study · 1
Kaplan and Irvin, likelihood of null effects of large NHLBI clinical trials has increased over time · PLoS One 2015;10(8):e0132382
How To Read A Study With The Money In View
Run these six checks on any study, in order.
- Find the funding and the conflicts. Scroll to the disclosure and funding statements at the end. A sponsor with a stake in the outcome does not disqualify the work; it tells you to read the rest slowly and to seek an outside replication.
- Check whether it was preregistered. Look for a public registration of its main outcome and analysis plan, filed before the trial began. Its absence is a reason to hold the finding loosely.
- Ask what was actually measured. Prefer a hard outcome that matters to a person, heart attacks or deaths, over a surrogate marker only assumed to track it. A drug can move the marker and do nothing for the outcome.
- Read the number, then the conclusion. Look at the primary result before the abstract's summary sentence. If the main outcome did not move but the abstract sounds positive, the positive tone usually comes from a secondary result. Check whether a small effect is being reported as a big one.
- Weight replication over any single study. One striking paper is a starting point. A finding that independent groups reproduce, especially groups with no stake in it, is the one to build on.
- Ask who benefits. Use it as the final filter. When a result is convenient for whoever paid for it, that is the result that most deserves an independent check.
The Limits of This Record
The named record here is small: 6 cases: a sugar trade group, tobacco, one hormone therapy, one painkiller, one antidepressant class, and OxyContin. That is enough to prove the practices are real and to teach the tells. It is not proof that every study is bought. Industry money pays for a great deal of essential research, and a sponsored study can be well designed and correct.
Scrutiny runs both ways. When a safety concern is waved off as settled, the people saying so are sometimes citing research funded by whoever profits from the product staying on the market. The tobacco industry ran exactly this play (Brandt 2012). These cases show how to read a study; they do not justify distrusting all research. Ask who paid whether a study raises an alarm or calms one.
Go Deeper
- How we grade evidence, the strength tiers behind the ladder on this topic.
- How to read a study, a single paper walked through line by line.
- Cholesterol and lipids, the field the 1967 review helped steer.
- Whole foods, the free, self-directed side of the same argument.
- The biology of aging: surrogate markers and hard outcomes, worked through.
Common Questions
Does industry funding mean a study is wrong?
No. The skew shows up across the literature as a whole; it says nothing about any single paper. One earlier review of more than 1,000 studies found industry-funded work about 3.6 times as likely to reach conclusions favorable to the sponsor as independently funded work (Bekelman 2003). The same review documented funders restricting publication and withholding data. Treat funding as a reason to read closely and to want an independent replication. It is not a reason to dismiss a single result on its own.
Was the sugar-versus-fat story really deliberate?
Yes. The internal correspondence documents the deliberate part. It does not settle the nutrition itself. That science has changed a lot in the nearly 60 years since. The lesson is narrow: hidden sponsorship made the review persuasive. It does not show that fat is harmless or that sugar by itself causes heart disease.
What is ghostwriting, exactly?
A company commissions professional writers to draft a journal article that favors its product, then recruits academic researchers to appear as the named authors. The paper reads as independent expert opinion while the content is the sponsor's. You can sometimes catch the trace in the acknowledgements, where a medical-communications firm is thanked for 'editorial assistance.'
If a treatment works, why would unpublished trials matter?
You cannot judge a treatment from the published trials alone. When the failures never publish, the trials that remain are the successes, so the average benefit reads higher than it is. For the antidepressants, the true average benefit was about a third smaller than the published trials suggested (Turner 2008). A review that also searches the trial registries beats a handful of standout papers.
What is the single most useful habit for reading past all this?
Check whether the study preregistered its main outcome, it is the fastest single tell. When advance registration became standard for large heart trials, the share reporting a benefit fell from 57% to 8% (Kaplan 2015).
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 9 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 10, 2026.